Fgfr Inhibitor and Chemotherapy in Gastric Cancer (Facing): Phase I Results from an Ecmc Combinations Alliance Phase I/II Trial of Azd4547 in Combination with Cisplatin and Capecitabine (Cx)

Aim: Fibroblast growth factors (FGFs) and their receptors (FGFRs) control a wide range of biological functions, and are implicated in the pathogenesis of diverse tumour types including gastro-oesophageal adenocarcinoma (OGA). AZD4547 is a potent, selective, small molecule inhibitor of FGFR 1, 2, & 3 tyrosine kinases. The aims of the phase I component of this study were to determine the safety, MTD, & PK profile of AZD4547 when administered with cisplatin (C) and capecitabine (X).